A Novel Bacterium, *Butyricimonas virosa*, Preventing HFD-Induced Diabetes and Metabolic Disorders in Mice via GLP-1 Receptor

Heetae Lee¹, Jinho An¹, Jiyeon Kim¹, Dohyun Choi¹, Youngcheon Song¹, Chong-Kil Lee², Hyunseok Kong³, Sang Bum Kim¹ and Kyungjae Kim¹*

¹College of Pharmacy, Sahmyook University, Seoul, South Korea, ²College of Pharmacy, Chungbuk National University, Cheongju, South Korea, ³College of Animal Biotechnology and Resource, Sahmyook University, Seoul, South Korea

Knowledge of the impact of the gut microbiota on human health has increased, and modulation of the bacterial community is now considered a therapeutic target for various diseases. Certain novel bacterial species have probiotic properties associated with improvement in obesity and related metabolic disorders. The relative abundance of *Butyricimonas* spp. is correlated with metabolic parameters; however, the physiological role of *Butyricimonas* in metabolic improvement is unclear. In this study, live and heat-killed *B. virosa* were administered to mice with high-fat diet (HFD)-induced obesity. Both live and heat-killed *B. virosa* ameliorated HFD-impaired body weight, serum glucose level, insulin resistance, and liver steatosis. Moreover, activation of the glucagon-like peptide-1 receptor (GLP-1R) and peroxisome proliferator-activated receptor α (PPARα) was observed in the liver, and the expression levels of insulin receptor substrate (IRS)-1, IRS-2, Toll-like receptor 5 (TLR5), and zonula occludens-1 (ZO-1) were upregulated in the ileum. Finally, we demonstrated that the effect of *B. virosa* treatment on glucose regulation may be linked to the upregulation of GLP-1R in the liver and is not a result of colonization of the gut by *B. virosa* or *B. virosa*-produced butyrate. Our results provide a rationale for the development of *Butyricimonas* spp.-based therapeutics and prophylactics for hyperglycemia.

Keywords: *Butyricimonas virosa*, gut microbiota, GLP-1 receptor, hyperglycemia, PPARα

INTRODUCTION

The effect of the gut microbiota on human health has been investigated in the past decade. The intestinal microbial ecology is considered an important factor in energy metabolism and the immune responses to various diseases (Boulange et al., 2016). Importantly, novel microbes residing in the human gut were identified by next-generation sequencing. Certain of these microbes were named pharmabiotics because they exerted therapeutic effects beyond those of probiotics. For example, *Akkermansia muciniphila* and *Faecalibacterium prausnitzii* are considered therapeutic targets for multiple diseases (Derrien et al., 2017; Martin et al., 2017; Depommier et al., 2019). Moreover, a recent human clinical study demonstrated that *A. muciniphila*...
significantly improved metabolic parameters (including insulin sensitivity and total cholesterol level), such that it is considered a pharmabiotic (Depommier et al., 2019).

Microbes with therapeutic effects on metabolic disorders including obesity, hyperglycemia, and hypercholesterolemia have been reported (Okubo et al., 2018). Potential pharmabiotic candidates typically have common properties, such as the ability to produce short-chain fatty acids (SCFAs), enhance gut barrier function, improve gut microbial imbalance, and regulate inflammatory immune responses (Nguyen et al., 2017). These beneficial effects are linked to improvements in insulin resistance and lipid metabolism, as well as reduced inflammation. Pharmabiotics in clinical and animal studies demonstrated multiple beneficial effects, indicating that targeting the gut microbiota is an intriguing therapeutic target for metabolic disorders (Okubo et al., 2018).

*Butyricimonas* is a Gram-negative anaerobic bacterial genus of the family *Odoribacteraceae*. They are present in the intestinal tract of several mammals, including rat and human (Sakamoto et al., 2009, 2014), but few species have been isolated (*B. faecihominis, B. synergistica, B. paravirosa, B. virosa,* and *B. phoceensis*). Treatment of metabolic disorders with metformin and statins significantly increased the relative abundance of *Butyricimonas* spp. in the gut, which was significantly correlated with metabolic parameters (Lee et al., 2018; Kim et al., 2019). However, the direct effect of *Butyricimonas* on metabolic improvements, and the underlying physiological mechanisms, have not been investigated.

The characteristics of *Butyricimonas* and our previous results support the hypothesis that *Butyricimonas* species are involved in commensal homeostasis between the gut microbiota and host, and exert a beneficial effect on host energy metabolism. To test this hypothesis, we investigated the metabolic effects induced by oral administration of live and heat-killed *Butyricimonas virosa* to mice with high-fat diet (HFD)-induced obesity. Furthermore, we conducted comparative analysis of metabolism-related transcripts.

**MATERIALS AND METHODS**

**Butyricimonas**

*Butyricimonas virosa* (KCTC 15148) was purchased from the Korean Collection for Type Cultures (KCTC) and cultured in Columbia broth supplemented with 5% horse serum under anaerobic conditions (i.e., in an anaerobic jar) at 37°C for 5 days. Cultured *B. virosa* (estimated 5 × 10⁸ CFU/ml optical density) was washed in phosphate-buffered saline (PBS) and stored at −70°C until inoculation, and their viability was confirmed using the spread plate method. In addition, heat-killed *B. virosa* were prepared by autoclaving for 15 min at 121°C and 15 lb.

**Animal Model**

Male 4-week-old C57BL/6N mice were purchased from Samtako Co., Ltd. (Osan, South Korea) and acclimated to laboratory conditions for 1 week, during which the animals were housed in a temperature and humidity-controlled animal facility under a 12 h light–dark cycle at 22 ± 2°C and 55 ± 5% humidity, with *ad libitum* access to water and food. Mice were fed a 60% kcal HFD (FeedLab, Inc., Guri, South Korea) to induce metabolic disorders—such as obesity, hyperglycemia, and hyperlipidemia—for 16 weeks. The mice were treated with *B. virosa* by oral gavage at 1 × 10⁸ CFU/200 μl (HFD-Bu: live *B. virosa* during HFD, *n* = 6), or HFD-hk-Bu: heat-killed *B. virosa* during HFD, *n* = 6) daily for the final 6 weeks of HFD feeding. A regular diet (RD, 10% kcal; Purina Korea, Inc., Seoul, South Korea)-fed group (*n* = 6) and HFD-fed group (HFD without *B. virosa*, *n* = 5) were included as normal and disease controls, respectively.

**Metabolic Analysis**

Body weight, serum glucose level, and food intake were recorded weekly. The serum glucose level was determined using the Accu-Chek Performa system (Roche Diagnostics, Mannheim, Germany) following fasting for 12 h (dark cycle). Intraperitoneal glucose tolerance testing (IPGTT) was performed 6 weeks after treatment with *B. virosa*. The mice were intraperitoneally injected with glucose solution (2 g/kg in PBS) after fasting 12 h (dark cycle), and the glucose level was measured by tail vein sampling using blood lancet at 15, 30, 60, and 120 min after injection. The incremental area under the curve (iAUC) for glucose was calculated for comparison of IPGTT results among time points. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index was used to evaluate insulin resistance (Matthews et al., 1985). Blood samples were collected by cardiac puncture and centrifuged at 10,000 rpm for 5 min to isolate serum. The serum levels of apolipoprotein B (ApoB), low-density lipoprotein (LDL), high-density lipoprotein (HDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were determined using a biochemical analyzer (AU480; Beckman Coulter, Brea, CA).

**Liver Histology**

Hepatic tissue was fixed in 10% neutral formalin. Tissue samples were filtered and embedded in paraffin, cut into 4-μm sections, and stained with hematoxylin and eosin (H&E). Sections were observed using a microscope (Nikon, Tokyo, Japan), and micrographs were taken at ×100 magnification. The percentage of steatosis in images was assessed using ImageJ software (Bethesda, MD).

**Transcriptome Analysis**

Ileum and liver tissues were immediately frozen in liquid nitrogen and stored at −70°C for later analysis of transcript levels. Total RNA was extracted using the RiboEx™ Kit (GeneAll, Seoul, South Korea). cDNA was synthesized using HyperScript™ RT Premix (GeneAll) according to the manufacturer’s instructions. SYBR Green PCR Master Mix and the StepOnePlus™ Real-Time PCR System (Applied Biosystems, Waltham, MA) were used to quantify mRNA levels. The following primer sets were used as: insulin receptor substrate (IRS)-1 (forward: 5′-TCCTATCCCG AAGAGGGTCT-3′; reverse: 5′-TGGGCCATATAGCCATCATCA-3′), IRS-2 (forward: 5′-TCGAGAACGCGCTCAACTAT-3′; reverse: 5′-AGTGATGGGACAGGAAGTCG-3′), glucagon-like peptide-1 (GLP-1) (forward: 5′-TCCTATCCCG AAGAGGGTCT-3′; reverse: 5′-TGGGCCATATAGCCATCATCA-3′).
receptor (GLP-1R; forward: 5′-TCAGAGACGGTGCAAGAAATG-3′; reverse: 5′-CAGCTGACATTCCAGAAGGA-3′), Dipeptidyl peptidase-4 (DPP4; forward: 5′-TTGTGGATAGCAA GCGAGTTG-3′; reverse: 5′-CACAGCTATTCCGCACCTGAA-3′), zonula occludens-1 (ZO-1; forward: 5′-GCTCATAGTTCA ACGACCTCAG-3′; reverse: 5′-TTTCTTCACAGCTGAAGGA CTCAACG-3′), peroxisome proliferator-activated receptor α (PPARα; forward: 5′-TCGCGGAACTATCCGGCT-3′; reverse: 5′-GCACTTGGAACAGGCGAGT-3′), PPARγ (forward: 5′-TTGGGATAAAACGATCAGG-3′; reverse: 5′-CCGGCAGTCAA GTACACACTAT-3′), Toll-like receptor 5 (TLR5; forward: 5′-AGTTCGGGGGAAATCTGTTT-3′; reverse: 5′-GCATAAGCTGAG GCTGTTTTC-3′), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH; forward: 5′-AACCATTGGGATGTGGAAGG-3′; reverse: 5′-ACACATTGGGGGTAGGAACA-3′).

Relative Abundance of Butyricimonas

The relative abundance of Butyricimonas in fecal samples was evaluated using SYBR® Green PCR Master Mix and the StepOnePlus™ Real-Time PCR System (Applied Biosystems). Fecal samples were collected 6 weeks after treatment with B. virosa. Total DNA was extracted using the PowerSoil DNA Isolation Kit (MO BIO Laboratories Inc., Carlsbad, CA) according to the manufacturer’s instructions. Primer sets for total bacteria (515f, forward: 5′-GTGCCAGCMGCCGCGTA-3′; 806r, reverse: 5′-GACTACHVHHRHTCTTAA-3′) and Butyricimonas (Buty1f, forward: 5′-GGTGAACAGAC GTGGCCAC-3′; Buty1r, reverse: 5′-TACCCCGCCAACTA CCTAATG-3′) were used for amplification.

Butyrate Analysis

Butyrate in feces was quantified using a modified version of a method published elsewhere (Cuervo et al., 2013; Jang et al., 2020). Homogenized mouse feces (10 mg/50 μl of PBS) was dried in a dry oven at 60°C to remove water. The dried sample was extracted with 500 μl of MeOH for 10 min in a shaking incubator. An internal standard, 4-methyvaleric acid (Sigma-Aldrich, St. Louis, MO), was added to the supernatant. The SCFA concentration was calculated using standard reagents (acetate, propionate, and butyrate; Sigma-Aldrich) with Autochrom-3,000 software and the VL6100 GC system, which was equipped with a flame ionization detector (FID) and capillary column (DB-Wax column, 30 m × 0.25 mm × 0.25 μm; Agilent Technology, Santa Clara, CA). The inlet and detector temperatures were set to 220°C. Samples (2 μl) were introduced by splitless injection. The oven temperature was initially maintained at 50°C for 1 min and then increased to 220°C at a rate of 10°C/min.

Western Blotting

Total liver protein was extracted using RIPA lysis buffer (GenDEPOT, Katy, TX) supplemented with a protease inhibitor cocktail solution (GenDEPOT). The homogenate was incubated at 4°C for 2 h. The protein concentration was measured by the Bradford method. Protein samples (20 μg) were subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h. They were then incubated at 4°C overnight with the primary anti-GAPDH antibody and anti-GLP-1R polyclonal antibody (1:1,000; Abcam, Cambridge, UK). After incubation with an anti-rabbit IgG horse radish peroxidase (HRP)-conjugated antibody (1:5,000; GenDEPOT) for 1 h, bands were detected using a chemiluminescent peroxidase substrate (ECL Plus; GenDEPOT) and imaged using the ChemiDoc XRS System (Bio-Rad, Hercules, CA).

Statistical Analysis

Data are presented as means ± standard error of mean (SEM). To quantify the in vivo mRNA levels relative to the internal control (GAPDH), the 2^−ΔΔCt relative quantification method ([ΔΔCt = (Ct_Gene − Ct_GAPDH)Group2 − (Ct_Gene − Ct_GAPDH)Group1]) was used. Statistical significance was assessed by Kruskal–Wallis H test, followed by Duncan’s post-hoc test. Statistical analysis was performed using RStudio (R Development Core Team, Vienna, Austria). A p-value of <0.05 was considered indicative of statistical significance.

RESULTS

Effect of B. virosa on Metabolic Disorders

Feeding the mice an HFD for 16 weeks induced weight gain; the average body weight of mice in the HFD group (46.5 ± 0.5 g) was significantly increased compared to that of mice in the ND group (32.0 ± 3.6 g). After treatment with B. virosa for 6 weeks, the body weight of mice in the HFD-Bu (44.7 ± 3.6 g) and HFD-hk-Bu (43.7 ± 5.7 g) groups was decreased compared to that of mice in the HFD group (48.2 ± 3.6 g) (Figure 1A). The mice in the HFD group gained 2.2 ± 1.2 g after the 6-week HFD, whereas those in the HFD-Bu and HFD-hk-Bu groups lost 2.2 ± 1.7 and 2.0 ± 0.8 g, respectively (Figure 1B). Daily food intake was not significantly different among the groups.

Treatment with B. virosa significantly improved serum glucose regulation. B. virosa significantly reduced the HFD-induced increase in fasting serum glucose levels in mice in the HFD-Bu (131.2 ± 17.6 mg/dl) and HFD-hk-Bu (137.1 ± 13.5 mg/dl) groups compared to the HFD group (180.2 ± 21.3 mg/dl; Figure 1C) after 6 weeks of B. virosa treatment and significantly ameliorated glucose tolerance (IPTGT; Figures 1D,E). Moreover, B. virosa reduced the serum insulin level in the HFD-Bu (3.2 ± 2.0 ng/dl) and HFD-hk-Bu (3.4 ± 1.0 ng/dl) groups compared to the HFD group (6.1 ± 3.6 ng/dl) and significantly improved the HOMA-IR scores (HFD: 3.4 ± 2.0; HFD-Bu: 1.1 ± 0.8 and HFD-hk-Bu: 1.2 ± 0.4; Figures 1F,G).

A significant decrease in the HFD-induced increased ALT and ApoB levels was observed in the HFD-Bu and HFD-hk-Bu groups compared to the HFD group, but the AST/ALT ratio was significantly improved only in the HFD-Bu group (Figures 2A–C). In addition, the LDL/HDL ratio was significantly decreased only in the HFD-Bu group (Figure 2D). Daily food intake was not significantly different among the groups.
Effect of Butyricimonas virosa on Liver Histology

The HFD-induced increased liver weight was significantly decreased by *B. virosa* treatment compared to the HFD group (Figure 3A). The severe liver steatosis in the HFD group was recovered by both live and heat-killed *B. virosa* (Figures 3B, C).

Quantification of *B. virosa* and Butyrate in Feces

The relative abundance of *B. virosa* was 6.3 ± 5.7% and 6.2 ± 1.3% in fecal samples from mice in the HFD-Bu and HFD-hk-Bu groups, respectively, which were significantly higher than in the HFD group (2.8 ± 1.2%; Figure 4A). Furthermore, the concentration of butyrate in fecal samples was significantly decreased in the HFD group (0.21 ± 0.08 mM) compared to the RD group (0.78 ± 0.35 mM; Figure 4B). The difference in concentration of butyrate between HFD and HFD-Bu groups was not statistically significant (Figure 4B). The difference in the levels of acetate and propionate between groups were also not significant (data not shown).

Transcriptome Analysis in the Liver and Ileum

HFD significantly downregulated the levels of GLP-1R (0.50 ± 0.23) and PPARα (0.62 ± 0.24) in the liver compared with RD (GLP-1R: 1.08 ± 0.38 and PPARα: 1.02 ± 0.24; Figure 5A). Treatment with *B. virosa* significantly upregulated the liver levels of GLP-1R in the HFD-Bu (0.67 ± 0.17) and HFD-hk-Bu (0.72 ± 0.22) groups, and of PPARα in the HFD-Bu (0.96 ± 0.14) and HFD-hk-Bu (1.15 ± 0.32) groups, compared to the HFD group (Figure 5A). The levels of DPP4 and PPARγ were not significantly different between the *B. virosa*-treated and HFD groups.

In the ileum, HFD significantly downregulated the levels of IRS-1 (0.64 ± 0.27), IRS-2 (0.54 ± 0.33), and ZO-1 (0.41 ± 0.31) compared with RD (IRS-1: 1.04 ± 0.30, IRS-2: 1.03 ± 0.29, and ZO-1: 1.02 ± 0.21), whereas the level of TLR5 was not significantly different between the RD (1.01 ± 0.17) and HFD (1.03 ± 0.64) groups (Figure 5B). Furthermore, *B. virosa* significantly upregulated the levels of IRS-1 in the HFD-Bu (1.35 ± 0.89) and HFD-hk-Bu (0.94 ± 0.47) groups, and those of IRS-2 in the HFD-Bu (1.32 ± 0.74) and HFD-hk-Bu (0.78 ± 0.42) groups, compared to the HFD group (Figure 5B). Moreover, *B. virosa* significantly upregulated the level of ZO-1 in the HFD-Bu (0.81 ± 0.34) and HFD-hk-Bu (0.71 ± 0.46) groups, and of TLR5 in the HFD-Bu (1.67 ± 0.68) and HFD-hk-Bu (1.37 ± 0.88) groups, compared to the HFD group (Figure 5B).
Regulation of GLP-1R in the Liver by *B. virosa*

The HFD-induced downregulation of the GLP-1R mRNA level in the liver was increased by heat-killed *B. virosa* (Figure 5A). In addition, the GLP-1R protein level in the liver, which was significantly decreased by the HFD, was upregulated by *B. virosa* compared to the HFD group (Figures 6A,B).

**DISCUSSION**

*Butyricimonas virosa* had a beneficial effect on metabolic disorders, including obesity and hyperglycemia, via GLP-1R in the liver in a mouse model of obesity. This finding is in agreement with a recent report that the abundance of *Butyricimonas* spp. is related to metabolic improvements (Lee et al., 2018; Kim et al., 2019). In addition, enrichment of *B. virosa* was observed in mice colonized with the microbiota of lean twins discordant for obesity (Ridaura et al., 2013). In a human study, a high level of the genus *Butyricimonas* was associated with significantly decreased triglyceride levels and body mass index (BMI; Fu et al., 2015). Interestingly, heat-killed *B. virosa* significantly ameliorated body weight gain, hyperglycemia, insulin resistance, and liver steatosis similarly to live *B. virosa*. Therefore, we considered that the metabolic improvements were not mediated by *B. virosa*-produced butyrate.

In this study, an increase in the relative abundance of *B. virosa* was identified in the fecal samples of mice in the HFD-Bu and HFD-hk-Bu groups but was significant only in the former group. We predicted that metabolic improvements would not be observed in the HFD-hk-Bu
Butyricimonas is a butyrate-producing bacterial genus and SCFAs, such as acetate, propionate, and butyrate, regulate the epithelial expression of genes involved in energy metabolism (Den Besten et al., 2013). Moreover, the administration of butyrate improved metabolic disorders, including hyperglycemia and hepatic lipogenesis, in a manner mediated by AMPK, GLUT4, and GLP-1 (Gao et al., 2019; Zhang et al., 2019).

FIGURE 4 | Quantification of Butyricimonas virosa and butyrate levels in feces. Fecal samples were collected at 6 weeks after treatment with B. virosa. Relative abundance of B. virosa analyzed using quantitative PCR (A), the concentration of butyrate was measured using gas chromatography (B). The relative abundance of B. virosa and the concentration of butyrate in fecal samples were significantly increased after treatment of B. virosa compared to HFD group.

FIGURE 5 | Transcriptome analysis in the liver (A) and ileum (B). Relative levels of mRNA associated with glucose regulation and lipid metabolism measured using quantitative PCR. The $2^{-\Delta\Delta CT}$ relative quantification method was used for analysis of the level of relative mRNA expression (log2 fold change) compared to that of GAPDH expression as an internal control. Different superscript letters indicate significant differences ($p<0.05$) according to Duncan’s post-hoc test. GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
Previous studies on *A. muciniphila* support the effect of heat-killed *B. virosa* on metabolic improvements. Live and pasteurized *A. muciniphila* at 70°C improved the metabolism of rodents and humans with obesity and diabetes (Depommier et al., 2019, 2020). Although it is unclear why heat-killed *B. virosa* induced metabolic improvements in this study, there are several plausible mechanisms. First, the effect of *B. virosa* may be mediated by a protein stable to autoclaving. Certain active bacterial components that mitigate insulin resistance and glucose tolerance are unaffected by heat treatment. Moreover, heat-killed *B. virosa* may modulate the gut microbiota and metabolic improvements. Although the effect of *B. virosa* on the gut microbiota was not investigated in this study, bacterial components and metabolites can act as prebiotics, modulating the gut microbiota (Salminen et al., 2021). Live and heat-killed *B. virosa* may have different modes of action, on which further studies are needed.

GLP-1R was implicated in glucose homeostasis following *B. virosa* treatment. Activation of GLP-1R is involved in regulation of hyperglycemia, and GLP-1R agonists including exenatide, liraglutide, and lixisenatide are important therapeutics for type II diabetes (Burcelin et al., 2014). Especially, GLP-1 secreted from intestinal cells activates glucose-dependent insulin secretion and inhibits glucagon release (MacDonald et al., 2002). SCFAs increase the secretion of GLP-1 and GLP-1R (Töhrurst et al., 2012; Zhang et al., 2019). Therefore, we hypothesized that the metabolic improvements induced by *Butyrivimonas* were caused by an increase in its SCFA production. However, the expression of GLP-1R in the intestine was not significantly increased by *Butyrivimonas* (data not shown). Interestingly, GLP-1R was upregulated in the liver, in which its activation is implicated in glucose regulation by *Butyrivimonas*. Indeed, GLP-1 is closely related to hepatocyte fatty acid β-oxidation and insulin sensitivity (Svegliati-Baroni et al., 2011), and GLP-1R in hepatocytes modulates insulin signaling, thereby ameliorating hepatic steatosis (Gupta et al., 2010). In this study, the hepatic steatosis induced by the HFD was improved by both live and heat-killed *B. virosa*; thus, *Butyrivimonas* may modulate hepatic lipogenesis via GLP-1R activation.

In addition, DPP4, which inactivates GLP-1, is an important therapeutic target for hyperglycemia. DPP4 regulation was not observed in this study, so may not be involved in GLP-1R-mediated glucose regulation by *Butyrivimonas*. Hepatic DPP4 is important in insulin resistance and the anti-diabetic effect of DPP4 inhibitors is mediated by upregulation of intact GLP-1 (Kim et al., 2016). However, an anti-glycemic effect of DPP4 inhibitors is apparent in mice lacking GLP-1R (Hansotia et al., 2004), and GLP-1R antagonism does not eliminate the anti-glycemic effect of DPP4 inhibitors in patients with T2D (Nauck et al., 2016). Moreover, GLP-1R agonists protect endogenous GLP-1 from degradation by DPP4 and are used in the treatment of T2D (Drucker et al., 2010).

PPARs are essential regulators of energy metabolism. Among them, PPARγ is a major therapeutic target for glucose regulation. Interestingly, the expression level of PPARγ was significantly increased, instead of that of PPARα. The role of PPARα in modulating glucose homeostasis is unclear. PPARα-null mice were protected against HFD-induced insulin resistance (Guerrero-Millo et al., 2001), and PPARα deficiency reduced insulin resistance in apoE-null mice (Tordjman et al., 2001). In contrast, the absence of PPARα increased hepatic glucose production from lactate and glycerol irrespective of the insulin level (Xu et al., 2002). Moreover, fibrates, which are selective PPARγ activators, improved HFD-impaired insulin sensitivity, thereby suppressing the expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and promoting insulin clearance (Guerrero-Millo et al., 2000; Ramakrishnan et al., 2016). PPARα regulates hepatic lipogenesis by modulating fatty acid uptake and oxidation (Pawlik et al., 2015). Insulin resistance is associated with hepatic steatosis and is a hallmark of non-alcoholic fatty liver (Chao et al., 2019). In this study, the HFD-induced increased liver weight and steatosis were significantly ameliorated by *B. virosa* treatment compared to the HFD group. Therefore, hepatic glucose regulation may be affected by fatty acid homeostasis via PPARα in the liver.

HFD-induced dysbiosis of the gut microbiota affects the expression of various genes related to energy metabolism,
inflammation, and lipid profiles (Boulange et al., 2016; Teixeira et al., 2021). In this study, live B. virosa ameliorated the HFD-induced downregulation of mRNA levels of IRS-1, IRS-2, ZO-1, and TLR5 in the ileum, likely related to the activation of GLP-1R for glucose regulation in the liver. A lack of insulin receptors in the intestine contributes to the pathophysiological changes seen in patients with type II diabetes (Ussar et al., 2017). The intestinal epithelial barrier, which is related to dysbiosis of the gut microbiota, affects liver function and insulin resistance (Dammns-Machado et al., 2017). ZO-1 is an important intracellular tight junction protein, whose disruption is linked to hyperglycemia (Thaiss et al., 2018). TLR5-deficient mice showed features of metabolic syndrome, including hyperglycemia and insulin resistance, which were significantly correlated with the altered gut microbiota (Vijay-Kumar et al., 2010).

Our findings suggest that B. virosa is implicated in glucose regulation in obese mice, but the absence of a mechanistic analysis was a limitation. We evaluated crosstalk between the gut microbiota and GLP-1R in the liver. Although B. virosa upregulated several mRNA transcripts in the intestine, we did not analyze downstream effects of GLP-1R activation in the liver. In addition, to generalize the anti-hyperglycemic effect of Butyricimonas, intervention studies using other animal models, including a non-obese diabetic mouse, are needed. Furthermore, investigation of Butyricimonas-induced changes in the gut microbiota under a variety of conditions would provide insight into the effect of Butyricimonas on glucose regulation.

CONCLUSION

Treatment with live and heat-killed B. virosa ameliorated changes in body weight, serum glucose level, insulin resistance, and liver steatosis in a mouse model of HFD-induced obesity. Moreover, GLP-1R in the liver was activated, which may be linked to in the metabolic improvements induced by Butyricimonas. Our results provide a rationale for the development of pharmaibotics based on Butyricimonas spp. for the prevention and treatment of type II diabetes.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by Institutional Animal Care and Use Committee (IACUC) of Sahmyook University (SYUIACUC 2019-004).

AUTHOR CONTRIBUTIONS

HL and KK: concept and design. JA, JK, DC, and HK: mouse model. HL, JA, JK, and DC: analysis or interpretation of data. HL: drafting of the manuscript. YS, CKL, HK, SBK, and KK: critical revision of the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

This manuscript has been edited by a native English speaker.

REFERENCES

Boulange, C. L., Neves, A. L., Chiloux, J., Nicholson, J. K., and Dumas, M. E. (2016). Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 8:42. doi: 10.1186/s13073-016-0303-2

Burrellin, R., Gourdy, P., and Dalle, S. (2014). GLP-1-based strategies: a physiological analysis of differential mode of action. Physiology 29, 108–121. doi: 10.1152/physiol.00009.2013

Chao, H. W., Chao, S. W., Lin, H., Ku, H. C., and Cheng, C. F. (2019). Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int. J. Mol. Sci. 20:298. doi: 10.3390/ijms20020298

Cuervo, A., Salazar, N., Ruas-Madiedo, P., Gueimonde, M., and Gonzalez, S. (2013). Fiber from a regular diet is directly associated with fecal short-chain fatty acid concentrations in the elderly. Nutr. Res. 33, 811–816. doi: 10.1016/j.nutres.2013.05.016

Dammns-Machado, A., Louis, S., Schnitzer, A., Volynets, V., Basrai, M., Cuervo, A., Salazar, N., Lin, H., Ku, H. C., and Cheng, C. F. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103. doi: 10.1038/s41591-019-0495-2

Depommier, C., Van Hul, M., Everard, A., Delzenne, N. M., De Vos, W. M., and Cani, P. D. (2020). Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes 11, 1231–1245. doi: 10.1080/19490976.2020.1737307

Derrien, M., Belzer, C., and De Vos, W. M. (2017). Akkermansia muciniphila and its role in regulating host functions. Microb. Pathog. 106, 171–181. doi: 10.1016/j.micpath.2016.02.005

Drucker, D. J., Sherman, S. L., Gorenlick, F. S., Bergenstal, R. M., Sherwin, R. S., and Buse, J. B. (2010). Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33, 428–433. doi: 10.2337/dc09-1499

Fu, J., Bonder, M. J., Cenut, M. C., Tiggeslaar, E. E., Maatman, A., Dekens, J. A., et al. (2015). The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ. Res. 117, 817–824. doi: 10.1161/CIRCRESAHA.115.306807

Gao, F., Lv, Y. W., Long, J., Chen, J. M., He, J. M., Ruan, X. Z., et al. (2019). Butyrate improves the metabolic disorder and gut microbiome Dysbiosis in mice induced by a high-fat diet. Front. Pharmacol. 10:1040. doi: 10.3389/fphar.2019.01040

Guerrre-Millo, M., Gervois, P., Raspe, E., Madsen, L., Poulain, P., Derudas, B., et al. (2000). Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638–16642. doi: 10.1074/jbc.275.22.16638
Lee et al. Butyricimonas virosa for Hyperglycemia

Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family ‘Porphyromonadaceae’ isolated from rat faeces. Int. J. Syst. Evol. Microbiol. 59, 1748–1753. doi: 10.1099/ijs.0.007674-0

Sakamoto, M., Tanaka, Y., Benno, Y., and Okhuma, M. (2014). Butyricimonas virosa sp. nov. and Butyricimonas parvispora sp. nov., isolated from human faeces, and emended description of the genus Butyricimonas. Int. J. Syst. Evol. Microbiol. 64, 2992–2997. doi: 10.1099/ijs.0.065318-0

Salmelin, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., et al. (2021). The international scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of probiotics. Nat. Rev. Gastroenterol. Hepatol. 18, 649–667. doi: 10.1038/s41575-021-00440-6

Svegliati-Baroni, G., Saccomanno, S., Rychlik, C., Agostinelli, L., De Minicis, S., Candelaresi, C., et al. (2011). Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 31, 1285–1297. doi: 10.1111/j.1478-3231.2011.02462.x

Teixeira, L. D., Torrez Lombardi, M. F., Debove-Scarlett, E., Bahadiroglu, E., Garrett, T. J., Gardner, C. L., et al. (2021). Lactobacillus johnsonii N6.2 and blueberry Phytophenols affect Lipidome and gut microbiota composition of rats Under high-fat diet. Front. Nutr. 8:757256. doi: 10.3389/fnut.2021.757256

Thaiss, A. C., Levy, M., Grossova, I., Zheng, D., Soffer, E., Blacher, E., et al. (2018). Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 359, 1376–1383. doi: 10.1126/science.aar3318

Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., et al. (2012). Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61, 364–371. doi: 10.2337/db11-1019

Tordjman, K., Bernal-Mizrachi, C., Zemamy, L., Seng, W., Feng, C., Zhang, F., et al. (2001). PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107, 1025–1034. doi: 10.1172/JCI11497

Ussar, S., Haering, M. E., Fujisaka, S., Latter, D., Lee, K. Y., Li, N., et al. (2017). Regulation of glucose uptake and Enteroendocrine function by the intestinal epithelial insulin receptor. Diabetes 66, 886–896. doi: 10.2337/db15-1349

Vijay-Kumar, M., Attik, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, S., Srinivasan, S., et al. (2010). Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 328, 228–231. doi: 10.1126/science.1179721

Xu, J., Xiao, G., Trujillo, C., Chang, V., Blanco, L., Joseph, S. B., et al. (2002). Faecalibacterium prausnitzii ‘Porphyromonadaceae’ isolated from rat faeces. Int. J. Syst. Evol. Microbiol. 52, 543. doi: 10.1099/ijs.0.0280883

Yamada, Y., Tsukiyama, K., Guerre-Millo, M., Rouault, C., Poulain, P., Andre, J., Poitout, V., Peters, J. M., et al. (2011). The role of the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 58, 1326–1335. doi: 10.2337/ diabetes.53.5.1326

Zhang, Y., Hu, J., Yang, Y., Suh, H. J., Hong, K. B., and Jo, K. (2020). Amylase-producing Maltooligosaccharide provides potential relief in rats with Loperamide-induced constipation. Evid. Based Complement. Alternat. Med. 2020, 1–9. doi: 10.1155/2020/5470268

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.